Buyers eye Relypsa and its hyperkalemia drug

ZS Pharma

While pharma M&A action has slowed, it is not dead. After AstraZeneca ($AZN) last year agreed to pay $2.7 billion for ZS Pharma ($ZSPH) it stoked interest in new treatments for the blood disorder hyperkalemia, and Relypsa ($RLYP) has one already approved, Veltassa. That, Reuters says, has drawn buyout interest, leading the Redwood City, CA-based biotech to hire an investment bank to check out its offers. Relypsa isn't commenting but the news service says several companies that had bid on ZS, including Actelion, are eyeing Relypsa. More from FierceBiotech


Suggested Articles

The Pharma Lions shortlist for 2019 lives up to its name with just 31 entries making the cut. But it's still good news for the 12 drugmaker finalists.

Pharma companies filed suit Friday to block the new HHS rule that requires drugmakers to put list prices in TV ads.

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.